REGN
Regeneron Pharmaceuticals Inc. Healthcare - Biotechnology Investor Relations →
Regeneron Pharmaceuticals Inc. (REGN) closed at $609.94 as of 2026-06-19, trading 20.9% below its 200-week moving average of $770.91. This places REGN in the extreme value zone. The stock is currently moving closer to the line, down from -20.6% last week. With a 14-week RSI of 25, REGN is in oversold territory.
Over the past 14 weeks, down-weeks have had more trading volume than up-weeks (0.65 buyers-vs-sellers ratio). That means when people are active, they're more often selling than buying. Sellers are still more in control than buyers.
Over the past 1789 weeks of data, REGN has crossed below its 200-week moving average 29 times. On average, these episodes lasted 24 weeks. Historically, investors who bought REGN at the start of these episodes saw an average one-year return of +19.6%.
With a market cap of $63.9 billion, REGN is a large-cap stock. The company generates a free cash flow yield of 5.1%, which is healthy. Return on equity stands at 14.5%. The stock trades at 2.0x book value.
Over the past 33.5 years, a hypothetical investment of $100 in REGN would have grown to $4100, compared to $3097 for the S&P 500. That represents an annualized return of 11.7% vs 10.8% for the index — confirming REGN as a market-beating investment and the kind of quality company where buying during 200-week moving average touches has historically been rewarded.
Free cash flow has been growing at a 3.5% compound annual rate, with 4 consecutive years of positive cash generation. A business generating more cash every year while trading below its 200-week moving average is exactly the kind of disconnect value investors look for.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: REGN vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After REGN Crosses Below the Line?
Across 29 historical episodes, buying REGN when it crossed below its 200-week moving average produced an average return of +14.7% after 12 months (median +9.0%), compared to +15.5% for the S&P 500 over the same periods. 67% of those episodes were profitable after one year. After 24 months, the average return was +47.8% vs +35.2% for the index.
Each line shows $100 invested at the moment REGN crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Bean Score Experimental
The Bean Score measures how far a stock's free cash flow yield has deviated from its own quarterly baseline, normalized by the stock's historical behavior. Between earnings dates, FCF is constant — so the score is purely a function of stock price. The levels below show at what prices REGN would reach each dislocation threshold.
Dislocation Price Levels
Prices where REGN's Bean Score would hit each σ threshold. Valid until next earnings report: 2026-07-30.
| Level | σ | Price | Signal |
|---|---|---|---|
| Deep Value | +2σ | $637.67 | Unusually cheap — potential buy zone |
| Value | +1σ | $677.64 | Cheap vs. own history |
| Fair Value | +0σ | $722.96 | Historical mean behavior |
| Expensive | -1σ | $774.78 | Expensive vs. own history |
| Deep Expensive | -2σ | $834.59 | Unusually expensive — potential trim zone |
Quarterly FCF & Yield Trailing twelve-month free cash flow and yield at each quarter end
Signal Accuracy Collecting Data
The Bean Score system is accumulating weekly data to validate signal accuracy. After 13+ weeks of history, this section will display win rates and average returns for each σ threshold crossing — answering the question: "When this score says cheap or expensive, does the price subsequently move in the expected direction?"
Theoretical framework — not backtested or forward-tested. The Bean Score uses trailing twelve-month free cash flow yield as a dislocation identifier. It measures whether the market has pushed a stock's yield unusually far from its own baseline behavior. These levels are reference points for identifying potential swing trade opportunities, not buy/sell signals. FCF values update quarterly with earnings; between reports, all movement is price-driven.
Dislocation Scores Experimental
Each score measures deviation from REGN's own historical baseline — the same idea as the Bean Score, applied to different fundamentals. Positive means cheaper or more dislocated than this stock's norm. Scores marked σ are normalized by the stock's own variability; pp values are simple deltas from its recent baseline.
Theoretical framework — not backtested. These scores describe how unusual today's readings are for this specific company. They are starting points for research, not buy or sell signals. Annual-statement scores (buyback, accruals, FCF vs history) rest on only ~4 yearly data points and are deltas, not sigmas.
Historical Touches
REGN has crossed below its 200-week MA 29 times with an average 1-year return of +19.6% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Apr 1992 | Nov 1992 | 32 | 41.4% | -10.3% | +4141.2% |
| Dec 1992 | Jan 1993 | 4 | 17.7% | +22.9% | +5024.8% |
| Feb 1993 | Apr 1993 | 8 | 10.5% | +6.6% | +4541.3% |
| Feb 1994 | Jul 1995 | 76 | 75.5% | -49.1% | +4372.6% |
| Nov 1995 | Nov 1995 | 3 | 14.3% | +83.0% | +5863.4% |
| Jan 1997 | Sep 1997 | 38 | 39.2% | -20.1% | +5555.0% |
| Oct 1997 | Dec 1999 | 113 | 46.5% | -21.0% | +5792.0% |
| Apr 2002 | Nov 2002 | 29 | 38.8% | -65.1% | +3171.2% |
| Dec 2002 | Dec 2005 | 158 | 72.6% | -36.7% | +2894.0% |
| May 2006 | May 2006 | 2 | 2.6% | +107.4% | +5029.1% |
| Jul 2006 | Jul 2006 | 2 | 8.7% | +54.8% | +5059.2% |
| Jun 2008 | Jul 2008 | 5 | 5.0% | +10.4% | +4049.6% |
| Nov 2008 | Dec 2008 | 3 | 13.6% | +32.3% | +4308.4% |
| Jan 2009 | Jan 2009 | 1 | 6.4% | +66.8% | +3849.8% |
| Feb 2009 | Jun 2009 | 16 | 25.4% | +71.6% | +4215.6% |
| Jun 2009 | Jul 2009 | 3 | 7.5% | +26.7% | +3506.9% |
| Oct 2009 | Nov 2009 | 3 | 14.4% | +55.6% | +3396.2% |
| Nov 2009 | Nov 2009 | 1 | 1.6% | +59.4% | +3299.5% |
| Jun 2016 | Jun 2016 | 1 | 1.6% | +52.4% | +81.2% |
| Oct 2016 | Nov 2016 | 3 | 6.9% | +19.1% | +69.2% |
| Dec 2016 | Apr 2017 | 17 | 8.6% | +2.4% | +67.5% |
| Oct 2017 | Jan 2019 | 64 | 30.7% | -17.9% | +50.3% |
| Feb 2019 | Feb 2019 | 1 | 2.1% | -6.1% | +51.2% |
| Mar 2019 | Jan 2020 | 44 | 28.8% | +22.8% | +52.7% |
| Jan 2020 | Feb 2020 | 2 | 9.9% | +55.8% | +78.1% |
| Nov 2024 | Nov 2024 | 1 | 1.4% | +2.9% | -16.7% |
| Dec 2024 | Dec 2025 | 53 | 36.0% | +1.9% | -15.9% |
| Jan 2026 | Feb 2026 | 3 | 4.0% | N/A | -16.6% |
| Mar 2026 | Ongoing | 16+ | 20.9% | Ongoing | -19.6% |
| Average | 24 | — | +19.6% | — |
Frequently Asked Questions
Is REGN below its 200-week moving average?
Yes. As of 2026-06-19, Regeneron Pharmaceuticals Inc. (REGN) is trading 20.9% below its 200-week moving average of $770.91. The current price is $609.94.
What is REGN's 200-week moving average price?
Regeneron Pharmaceuticals Inc.'s 200-week moving average is $770.91 as of 2026-06-19. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when REGN drops below its 200-week moving average?
REGN has crossed below its 200-week moving average 29 times in our data. On average, buying at that moment produced a one-year return of +19.6%. These dips have historically been decent entry points. These episodes lasted 24 weeks on average.
Is REGN a good value right now?
Here's what our data says about REGN as of 2026-06-19: The stock is below its 200-week moving average, which is the starting point for our analysis. The 14-week RSI is 25 (oversold). Free cash flow yield is 5.1%. Return on equity is 14.5%. Price-to-book is 2.0x. This is not a buy or sell recommendation — always do your own research.
How does REGN compare to the S&P 500?
Over the past 33.5 years, $100 invested in REGN would have grown to $4100, compared to $3097 for the S&P 500. That's 11.7% annualized vs 10.8% for the index. REGN has outperformed the broader market over this period.
Does REGN pay a dividend?
Yes. Regeneron Pharmaceuticals Inc. currently pays a dividend yield of 61.00%.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-06-19